Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II study

@article{Metzgeroth2008SafetyAE,
  title={Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II study},
  author={Georgia Metzgeroth and Christoph Walz and Philipp Erben and Helena Popp and Annette Schmitt-Graeff and Claudia Haferlach and Alice Fabarius and Susanne Schnittger and David Grimwade and Nicholas C. P. Cross and R{\"u}diger Hehlmann and Andreas Hochhaus and Andreas Reiter},
  journal={British Journal of Haematology},
  year={2008},
  volume={143}
}
This study evaluated the efficacy and safety of imatinib in chronic eosinophilic leukaemia (CEL, n = 23) and hypereosinophilic syndrome (HES, n = 13). In CEL with FIP1L1‐PDGFRA (n = 16) or various PDGFRB fusion genes (n = 5), complete haematological remission (CHR) was achieved in 95% (20/21) after 3 months. Complete molecular remission (CMR) was seen in 75% (12/16) of cases with FIP1L1‐PDGFRA positive CEL by 6 months, and in 87% (13/15) after 12 months. CMR was achieved in three of five PDGFRB… Expand
Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia
TLDR
Long-term results of F/P-positive CEL patients with chronic eosinophilic leukaemia harbouring the FIP1L1-PDGFRα (F/P) fusion transcript and the response rate after imatinib are presented. Expand
Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome
TLDR
It is suggested that IM, even at lower than conventional doses, may induce and maintain long-term remission for FIP1L1-PDGFRα-negative HES. Expand
Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1‐PDGFRA fusion transcript—results of Polish multicentre study
TLDR
Significant clinical symptoms are infrequent present and splenomegaly remains the most common organ involvement in patients with CEL expressing F/P fusion transcript, and the long‐term remission on imatinib in this patient population is confirmed. Expand
Chronic eosinophilic leukemia‐not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation
TLDR
Three patients with CEL-NOS are alive in complete remission; first underwent allogeneic stem-cell transplantation preceding by intensive induction chemotherapy; the second remains on imatinib with hydroxyurea. Expand
Long-term outcomes of imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China
TLDR
A 100 mg daily dose of imatinib is sufficient to induce remission, and a single 100 mg weekly dose maintains a durable remission in patients with F/P mutated CEL. Expand
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study
TLDR
Nilotinib 400 mg twice daily was effective in some patients with HES/CEL regardless of F/P mutation status, and the safety profile was consistent with other nilotinib studies. Expand
[Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome].
TLDR
The association of polyserositis with hypereosinophilic syndromes and the potential efficacy of imatinib mesylate even in FIP1L1-PDGFRA-negative patients is evidences. Expand
Imatinib for the treatment of hypereosinophilic syndromes
  • G. Helbig
  • Medicine
  • Expert review of clinical immunology
  • 2018
TLDR
Imatinib mesylate, a first generation tyrosine kinase inhibitor, has revolutionized the therapeutic approach to patients with hypereosinophilic syndromes and detectable F/P fusion gene. Expand
Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report
TLDR
A case demonstrates successful treatment of EGPA with IM, a key pharmacological agent in treating various types of hematological malignancies and FIP1L1/PDGF-RA-positive hypereosinophilia. Expand
A short low‐dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes
TLDR
Low‐dose, short‐course imatinib may represent a rational choice for identifying responsive cases, both within and outside the pre‐defined FIP1L1 rearrangement subset. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
The results of imatinib therapy for patients with primary eosinophilic disorders
TLDR
A subset of patients with FIP1L1-PDGFRA -positive HES demonstrated rapid clinical improvement and hematologic/molecular remission after imatinib therapy, and a complete hematological remission defined as peripheral eosinophilia count <0.7 · 10/L was achieved in three patients. Expand
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma
TLDR
All eosinophilia-associated hematological malignancies should be screened for the presence of the FIP1L1-PDGFRA fusion gene as they are excellent candidates for treatment with tyrosine kinase inhibitors even if they present with an aggressive phenotype such as AML. Expand
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study
TLDR
All patients meeting the criteria for idiopathic or primary HES should be screened for the FIP1L1-PDGFRα rearrangement, and chronic imatinib treatment at doses as low as 100 mg daily ensures complete and durable responses. Expand
Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias
TLDR
FIP1L1-PDGFRA (+) CEL emerges as a homogeneous clinicobiological entity, where imatinib can induce molecular remission, and while RT-PCR and interphase FISH are equally valid diagnostic tools, the role of marrow biopsy in diagnosis and of RQ- PCR in disease and therapy monitoring needs further evaluation. Expand
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
TLDR
It is found that it is possible to maintain patients in clinical remission with an empirically derived schedule of low-dose (50-100 mg), intermittent (once daily to once weekly) imatinib. Expand
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
TLDR
Real-time quantitative-polymerase chain reaction assays are consistent with the exquisite sensitivity of the FIP1L1-PDGFRalpha fusion to imatinib, as compared with BCR-ABL, and underline the importance of RQ-PCR monitoring to guide management using molecularly targeted therapies. Expand
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
TLDR
Imatinib mesylate induces durable responses in patients with chronic myeloproliferative diseases associated with activation of PDGFRB and all responses were durable at 9 to 12 months of follow-up. Expand
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.
TLDR
FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis. Expand
The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
TLDR
FISH is a reliable diagnostic test for differentiating 4q-/CEL from other forms of HES, allowing an early diagnosis of good responders to imatinib mesylate therapy and for the first time it is shown that PDGFRB, FGFR1, ABL1 and ETV6 are not rearranged in HES. Expand
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
TLDR
The data show that durable hematologic and cytogenetic responses are achieved with imatinib in patients with PDGFRB fusion-positive, BCR-ABL-negative CMPDs. Expand
...
1
2
3
4
...